Kimberley Standard
Drug List
 In
consultation with a number of key stakeholders, KAMSC and KHR have
developed a standard drug list for use in the Kimberley, the first
edition being published in November 2005. This standard drug list is
largely defined by best practice guidelines and is intended to be used
by Aboriginal community controlled health services and remote government
clinics. It is also intended to be reflected in hospital imprest systems.
It is hoped that this process of drug rationalization promotes consistency
in care across health services and consequently, have widespread benefits
for both clinicians and patients.
In order to establish a regional consensus, the first stage of development
involved circulation of a comprehensive drug list to Kimberley clinicians.
The drug list included therapeutic classes relevant to the health priorities
of the Kimberley population. Clinicians were asked to select their preferences
in each therapeutic class and provide rationale for these preferences.
A 3-part format for the standard drug list was established as follows:
1) Essential drug list: This list consists of drugs that the steering committee
recommends should be easily accessible to the Kimberley population and hence,
included in all clinic medication imprests.
2) Supplementary list: This list consists of drugs that should be able to be
accessed across the Kimberley, but will not be required by all clinics. Therefore,
it is at the discretion of the senior clinicians as to whether or not these drugs
are included on the clinics imprest. Drugs on the supplementary list are included
for specific indications.
3) Emergency drug list: Drugs for inclusion in Emergency drug kits.
A KSDL Review Committee has been established to facilitate the updating and ongoing
maintenance of this standard list. The committee meets twice a year to review
any new drugs which have been added to the PBS, new clinical data that has been
reported, and also to review any KSDL modification request forms submitted by
clinicians. The review takes into account the following criteria:
• Evidence based medicine/clinical trial data
• Regional preferences
• PBS indications and authority status (if applicable)
• Familiarity
• Drug costs
• Side Effect Profile/Interactions
• Patient Compliance
Other Resources
The KSDL is a constant work in progress, and will be reviewed every 6 months
by the KSDL Review Committee. Please review the Summary
Table for the most recent changes to the KSDL. For
further information, please refer to the minutes of
the meeting which was held on April 23rd 2007.
The KSDL will be re-printed every 2nd edition, to coincide with every
2nd KSDL review meeting. The current printed version is the August
2006, 2nd Edition
- please place the Summary table as listed above into the front sleeve
of all 2nd
edition printed copies.
Alternatively, the current 3rd edition can be printed from the link below:
Downlod
your copy of the current KSDL - Pocket PC /
PDA version.
For further information, please contact either:
(i) Corina
Pesich - KAMSC Pharmacist on (08) 9193 6043
(ii) Roy
Finnigan - WACHS Regional Pharmacist on (08) 9194 2000
Page last updated
Monday, November 5, 2007 12:08 PM
|
